BioArctic Q2 FY26 turns to net loss of SEK 11.2 million; revenue falls to SEK 247.5 million

Reuters2026/08/26 06:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BioArctic swung to an operating loss of SEK 6.5 million in April–June 2026 as net revenues fell to SEK 247.5 million.
Profit for the period turned to a loss of SEK 11.2 million; earnings per share were SEK -0.13.
Royalty income from Leqembi rose to SEK 179.4 million; global Leqembi sales climbed to JPY 29.3 billion.
Eisai forecast fiscal 2026 Leqembi sales of JPY 143.5 billion, implying 63% growth versus the prior year.
BioArctic signed a BrainTransporter collaboration with Eli Lilly, including a USD 30 million upfront and up to USD 800 million milestones.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioArctic AB published the original content used to generate this news brief via Cision (Ref. ID: 20260825:BIT:2127:0) on August 26, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BioArctic Q2 FY26 turns to net loss of SEK 11.2 million; revenue falls to SEK 247.5 million

You may also like

Crypto prices